Ecstasy ingredient MDMA granted ‘Breakthrough Therapy Designation’ status

Ecstasy ingredient MDMA granted ‘Breakthrough Therapy Designation’ status

Supporting the need for medical research on psychedelic substances, the U.S. Food & Drug Administration (FDA) recently granted the ecstasy ingredient MDMA "Breakthrough Therapy Designation" status.

The term of “Breakthrough Therapy Designation” means that the federal agency will expedite the development as well as review of the ecstasy drug. This status is granted to those substances that are projected to treat a grave or life-threatening health condition.

The Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit group that has long been advocating for medical research on psychedelic substances, welcomed the federal agency’s decision.

In a newly released statement, MAPS said, “By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD.”

The nonprofit has already funded a series of clinical trials aimed at looking into the use of MDMA in conjunction with psychotherapy as a potential treatment for PTSD. With the new status from the top watchdog, the nonprofit will move forward with Phase 3 of the clinical trials, which are expected to take place in 2018.

Tags: 
Category: